Ceo
CurrentEyeGene, Inc. : Accomplishments of R&D / Business Development / IPO(Sep. 2000 – Mar. 2016) www.eyegene.co.kr• IPO in KOSDAQ Listed (2015.11)• IPO in KONEX Listed (2013.11)• Development of Therapeutics of Diabetic Retinopathy (“EG-Mirotin”): pre-clinical in Korea & EU, Clinical Phase I in Netheland, NOW Clinical Phase IIa in France• Development of Therapeutics of Chronic Ulcer, Bedsore (“EG-Decorin”): pre-clinical in Korea, NOW Clinical Phase I & II in Korea w/ HUONS• Development of Human Papilloma Vaccine (“EG-HPV”): pre-clinical in Korea & EU, Clinical Phase I in Korea, NOW Clinical Phase II preparation in Korea • Development of Novel Vaccine Adjuvant (“EGvac”) • Development of Therapeutics of fibrosis (Scarless wound healing for eye : “EGS001”): Identification using proteomics of human amniotic membrane NOW Clinical Phase I&II preparation in Korea• Development of Diagnostics of Diabetes Complication (such as Diabetic Retinopathy): Bio-marker Identification using proteomics : from human eye• Development of Immunotherapeutics of cancer (“Zycan”) : pre-clinical stage, pilot production, Animal test (Efficacy:Animal model) (bladder cancer, melanoma, colon cancer & prostate cancer)- Technological Transfer to Pharmaceutical company (Domestic)1. Human papiloma vaccine : ChongKunDang Pharm (CKD pharm) (2009)- Co-development of vaccine / technology Licencing-out(Korea/China)- “super biosimilar”2. Therapeutic for Chronic Ulcer : “HUONS” (2009)- Co-development of BIO new drug / technology Licencing-out(Korea)3. Immunotherapeutics of cancer : Daewoong Pharmaceuticals (2002)- Co-development of new drug (pending)4. Diagnostics of Diabetic Retinopathy : Kuhnil Pharmaceuticals (2004)- Licence-out (pending)
